TB-PRACTECAL: Efficacy and Safety of Three 24-Wk Oral Regimens for Pulmonary Rifampicin-Resistant TB in Persons With HIV

July 29-August 2, 2022; Montreal, Quebec
Bedaquiline, pretomanid, and linezolid with or without clofazimine or moxifloxacin for 24 weeks appeared to be generally safe and effective for the treatment of rifampicin-resistant TB in both people with and without HIV in this randomized, open-label phase II/III trial.
Format: Microsoft PowerPoint (.ppt)
File Size: 275 KB
Released: August 4, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences, Inc.
ViiV Healthcare

Related Content

Dr William R. Short: key considerations for the use of long-acting cabotegravir and rilpivirine in pregnancy, from Clinical Care Options (CCO)

William R. Short, MD, MPH, AAHIVS Released: September 28, 2022

Expert selections of important HIV data from AIDS 2022, including current and investigational strategies for prevention, ART, comorbidities, and cure

Joseph J. Eron, Jr., MD Jeffrey Kwong, DNP, MPH, FAANP, FAAN Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP David A. Wohl, MD Released: September 23, 2022

Expert selections of important HIV data from AIDS 2022, including current and investigational strategies for prevention, ART, and comorbidities

Jeffrey Kwong, DNP, MPH, FAANP, FAAN Released: September 23, 2022

An expert panel of healthcare professionals and patient advocates discuss barriers faced by aging patients with HIV, from Clinical Care Options (CCO)

Jonathan Appelbaum, MD, FACP, AAHIVS
Program Director
Lydia Mungherera, MBChB Cristina Mussini, MD Dorothy Onyango Melanie Reese Marc Thompson
Released: September 23, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings